GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) » Definitions » Other Current Assets

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Other Current Assets : HK$84.28 Mil (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is ImmuneOnco Biopharmaceuticals (Shanghai) Other Current Assets?

ImmuneOnco Biopharmaceuticals (Shanghai)'s other current assets for the quarter that ended in Dec. 2023 was HK$84.28 Mil.

ImmuneOnco Biopharmaceuticals (Shanghai)'s quarterly other current assets declined from Dec. 2022 (HK$17.46 Mil) to Jun. 2023 (HK$9.23 Mil) but then increased from Jun. 2023 (HK$9.23 Mil) to Dec. 2023 (HK$84.28Mil).

ImmuneOnco Biopharmaceuticals (Shanghai)'s annual other current assets declined from Dec. 2021 (HK$43.74 Mil) to Dec. 2022 (HK$17.46 Mil) increased from Dec. 2022 (HK$17.46 Mil) to Dec. 2023 (HK$84.28 Mil).


ImmuneOnco Biopharmaceuticals (Shanghai) Other Current Assets Historical Data

The historical data trend for ImmuneOnco Biopharmaceuticals (Shanghai)'s Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuneOnco Biopharmaceuticals (Shanghai) Other Current Assets Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data
Trend Dec21 Dec22 Dec23
Other Current Assets
43.74 17.46 84.28

ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Other Current Assets Get a 7-Day Free Trial - 17.46 9.23 84.28 -

ImmuneOnco Biopharmaceuticals (Shanghai) Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


ImmuneOnco Biopharmaceuticals (Shanghai) Other Current Assets Related Terms

Thank you for viewing the detailed overview of ImmuneOnco Biopharmaceuticals (Shanghai)'s Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmuneOnco Biopharmaceuticals (Shanghai) Business Description

Traded in Other Exchanges
N/A
Address
1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.
Executives
Gba Fund Investment Limited 2101 Beneficial owner
Jia Xing Han Ning Qi Ye Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Halo Biomedical Lp 2201 Interest of corporation controlled by you
Halo Biomedical Investment Ii Limited 2101 Beneficial owner
Halo Biomedical Investment I Limited 2201 Interest of corporation controlled by you
Tian Wenzhi 2501 Other
Lav Immon Hong Kong Limited 2101 Beneficial owner
Greater Bay Area Homeland Investments Limited 2201 Interest of corporation controlled by you
Greater Bay Area Homeland Development Fund (gp) Limited 2201 Interest of corporation controlled by you
Ho Yao
Lav Immuneonco Hong Kong Limited 2101 Beneficial owner
Lav Gp V, L.p. 2201 Interest of corporation controlled by you
Lav Corporate V Gp, Ltd. 2201 Interest of corporation controlled by you
Lav Biosciences Fund V, L.p. 2201 Interest of corporation controlled by you
Shi Yi 2201 Interest of corporation controlled by you

ImmuneOnco Biopharmaceuticals (Shanghai) Headlines

No Headlines